Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenvatinib + gemcitabine + oxaliplatin is a combination regimen consisting of three drugs: lenvatinib, a multi-targeted tyrosine kinase inhibitor with antiangiogenic and antiproliferative properties; gemcitabine, a nucleoside analog that inhibits DNA synthesis; and oxaliplatin, a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. This combination has been investigated primarily for the treatment of advanced or unresectable fibrolamellar carcinoma (FLC) and intrahepatic cholangiocarcinoma (ICC), particularly in patients who are not candidates for surgery or have relapsed/progressed after prior therapies. The rationale for this regimen is to combine the cytotoxic effects of chemotherapy (gemcitabine/oxaliplatin) with the targeted inhibition of tumor angiogenesis and growth signaling pathways by lenvatinib[1][2][3].
- Other names
- GEMOX-LENGOL
02
Targets
DNAKIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)CDA (Cytidine deaminase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on lenvatinib + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + gemcitabine + oxaliplatin.